Celgene (CELG) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Celgene Reports Fourth Quarter and Full Year 2015 Operating and Financial Results
January 28, 2016 7:30 AM ESTData from at Least 18 Phase III Trials Expected from Mid-2016 Through Mid-2018 2016 Guidance for Total Net Product Sales, REVLIMID® Net Sales and Diluted EPS
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) reported operating results for the fourth quarter and full year of 2015. For the fourth quarter of 2015, net product sales were $2,539 million compared to $2,055 million from the same period in 2014, an increase of 24 percent. The net negative impact of currency on net product sales was 1 percent.... More
